Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41593-024-01582-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.
Addiction
January 2025
Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA.
Background And Aims: The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing needs. Psychedelics are emerging as a possible alternative therapy for mental health and substance use disorders. This study aimed to gather insights on how people use or are considering using psychedelics to manage opioid use disorder (OUD), how these experiences are perceived to impact opioid use and what these lessons imply for future research and practice.
View Article and Find Full Text PDFComparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada.
Subst Use Addctn J
November 2024
British Columbia Centre on Substance Use, Vancouver, BC, Canada.
Article Synopsis
- The study investigates the impact of opioid agonist therapy (OAT) on methamphetamine and amphetamine use among individuals with opioid use disorder (OUD) in Canada, comparing buprenorphine/naloxone and methadone.
- Conducted over 24 weeks, data from a pan-Canadian trial highlighted that both treatments showed no significant effect on reducing methamphetamine/amphetamine use, as assessed through drug testing and self-reporting.
- Despite methamphetamine/amphetamine use being prevalent among participants, results indicated that neither treatment method led to notable changes in their usage patterns throughout the study period.
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.
Pharmaceuticals (Basel)
November 2024
College of Science, Health and Pharmacy, Roosevelt University, Schaumburg, IL 60173, USA.
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs). Despite early mid-20th century anecdotal reports and pilot studies demonstrating the possibility of these substances in efficaciously treating conditions such as alcohol and opioid use disorders, legal restrictions and social stigma have historically hindered further research into this area. Nevertheless, concurrent with the rise in SUDs and other mental health conditions, researchers have again turned their attention to these compounds, searching for differing pharmacological targets as well as more holistic treatments that might increase patient adherence and efficacy.
View Article and Find Full Text PDFThe decriminalization of illicit drugs in British Columbia: a national evaluation protocol.
BMC Public Health
October 2024
Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), 250 College St., Toronto, ON, M5T 1R8, Canada.
Background: On January 31st, 2023, the province of British Columbia (BC), Canada, was granted a federal exemption allowing adults (aged 18 +) to possess up to 2.5 g of select illicit drugs. The exemption will be in place for three years (2023-2026), marking the first formal decriminalization of illicit drug policy reform in Canada.
View Article and Find Full Text PDFHarnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy.
Clin Pharmacol Ther
January 2025
Psychae Therapeutics, Melbourne, Victoria, Australia.
Psychedelics have recently re-emerged as potential treatments for various psychiatric conditions that impose major public health costs and for which current treatment options have limited efficacy. At the same time, personalized medicine is increasingly being implemented in psychiatry to provide individualized drug dosing recommendations based on genetics. This review brings together these topics to explore the utility of pharmacogenomics (a key component of personalized medicine) in psychedelic-assisted therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!